Ardelyx, Inc. ARDX

US Biotechnology

$2.98 ▲ +1.71% (+$0.05)

Open $2.92

Prev Close $2.93

Day Range $2.90 – $2.99

52W Range $2.80 – $8.40

Market Cap $736.52M

Beta 0.77

EPS (TTM) $-0.23

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2014-06-19
Shares Out.	249,190,000
Website	ardelyx.com/ ↗
Phone	13026974590
Employees	489
Revenue	$127.7M
Gross Profit	$123.1M
Net Income	-$737,000
Free Cash Flow	-$16.0M
Total Assets	$587.5M
Total Liabilities	$423.5M
Equity	$164.0M

About Ardelyx, Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Ardelyx, Inc. is a publicly traded company under the ticker symbol ARDX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.